BIO’s Preclinical Safety Committee (BioSafe) will hold its BioSafe European General Membership Meeting at AbbVie in Ludwigshafen, Germany on November 4-5. The meeting’s goal is to provide industry experience and perspectives gained to help ensure common understanding and continued application of scientific principles with respect to key issues in preclinical safety evaluation of biopharmaceuticals.
For more information or if you have problems registering, please contact Victoria Dohnal
The mission of BioSafe is to serve as a resource for BIO members and BIO staff by identifying and responding to key scientific and regulatory issues related to the preclinical safety evaluation of biopharmaceutical products.
The General Membership consists of over 30 companies who work on white papers, responses to regulatory guidance, and expert topic meetings. These companies also make up various ad hoc subcommittees including the Specialty Biologics Expert Working Group, and the PK/PD Working Group.
About the Meeting:
When: November 4-5, 2015
Where: AbbVie Ludwigshafen, Germany
Who: BIO members engaged in the conduct and reporting of preclinical safety evaluations for biopharmaceuticals.
Registration: This meeting is open to BIO member company staff engaged in the conduct and reporting of preclinical safety evaluation for biopharmaceuticals. Registration is not limited to BioSafe members, but your company must be a member of BIO. Registration is $175 (approximately €150) to cover the cost of the meeting. Registration closes Friday, October 23rd.
Registration has now closed.
BioSafe is a committee within BIO's Health Section, comprised of BIO members working to identify key scientific and regulatory issues and developments related to the preclinical safety evaluation of biopharmaceutical products and recommending appropriate science-based responses.